Last reviewed · How we verify
NCT06909409
D Vitamin and Alveolar Macrophages in Idiopathic Pulmonal Fibrosis
trial in Idiopathic Pulmonary Fibrosis (IPF) in 120 participants. Currently enrolling.
11 October 2026
Quick facts
| Lead sponsor | University of Aarhus |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 11 October 2024 |
| Primary completion | 11 October 2026 |
| Estimated completion | 11 October 2026 |
| Sites | 1 location across Denmark |
Conditions studied
- Idiopathic Pulmonary Fibrosis (IPF) — all drugs for Idiopathic Pulmonary Fibrosis (IPF) →
Sponsor
University of Aarhus
Who can join
18 and older, any sex, with Idiopathic Pulmonary Fibrosis (IPF). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to gain deeper insights into human macrophages and vitamin D, and their interplay, within Idiopathic Pulmonary Fibrosis (IPF). The overall questions, it aims to answer, are the following: Do IPF patients suffer from systemic and local (pulmonary) insufficient levels of vitamin D? Do IPF patients suffer from pro-fibrotic and pro-inflammatory pulmonary macrophages?
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06909409
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Idiopathic Pulmonary Fibrosis (IPF)
Currently open trials in the same condition.
- NCT07482917 — Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial · NA · recruiting
- NCT07486206 — Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial · NA · recruiting
- NCT06968845 — A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis · Phase 2 · recruiting
- NCT07466420 — Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases. · NA · recruiting
- NCT07464912 — A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic · Phase 3 · recruiting
Other University of Aarhus trials
Trials by the same sponsor.
- NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
- NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
- NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
- NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06909409 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
- Last refreshed: 3 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06909409.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing